Exhibit
10.26


 


PROCESS
DEVELOPMENT AGREEMENT


ACCORDION
PILLTM CARBIDOPA LEVODOPA


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 




    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.


     


    

 


	Article
    I         Definitions	5
	General	5
	1.01	“ACCORDION PILL”	5
	1.02	“ACCORDION PILL PRODUCTION LINE”	5
	1.03	“ACTIVE PHARMACEUTICAL INGREDIENT/ API”	5
	1.04	“Affiliate”	6
	1.05	“Agreement”	6
	1.06	“BUSINESS DAY”	6
	1.07	“Clinical Samples”	6
	1.08	“CMC Part”	6
	1.09	“Commercially
    Reasonable Efforts”	6
	1.10	“COMPONENTS”	7
	1.11	“Control”	7
	1.12	“Defective
    Product”	7
	1.13	“Development
    Activities”	7
	1.14	“Development
    Plan”	7
	1.18	“Manufacturing
    Agreement”	8
	1.19	“Product”	8
	1.20	“Project”	8
	1.21	“Specifications”	9
	Article
    II        Cooperation; Scope of Work	9
	Article
    III       EQuipment	10
	Article
    IV      Contribution of LTS	13
	4.01	LTS Contribution	13
	4.02	Changes to the Development
    Plan and additional LTS activities	13
	4.03	Estimated timelines
    and costs	13
	4.04	LTS’ Support
    of Registration	14
	4.05	Audit at LTS	15
	4.06	QUALITY AGREEMENT	15
	Article
    V        Contributions of INTEC	15
	5.01	API Supply	15
	5.02	DATA TRANSFER	16
	5.03	Evaluating Results	16
	5.04	Clinical Trials	17
	5.05	Registration of Products	17
	Article
    VI      TECHNICAL WORKING GROUP	17
	Article
    VII     Compensation	17
	7.01	INTEC Funding of
    Development Activities	17
	7.02	Payment Terms	18
	7.03	Payment terms	19
	7.04	Expenses	19
	Article
    VIII    Confidentiality	19
	Article
    X        Future Rights	21
	Article
    XI      Liability and Indemnification	21
	11.01	Supply of Samples	21
	11.02	Replacement	21
	11.03	Product Liability	22
	11.04	Volunteer Insurance	22
	11.05	Acknowledgement	23
	11.06	No Indirect, Punitive
    or Exemplary Damages	23
	11.07	No warranty	23


 



    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
2


     


    

 


	Article
    XII     Term and Termination	23
	Article
    XIII    Miscellaneous Provisions	26
	13.01	No Waiver	26
	13.02	ASSIGNMENT	26
	13.03	Involvement of Third
    Parties by LTS	26
	13.04	Involvement of Third
    Parties by INTEC	27
	13.05	No Agency	27
	13.06	Force Majeure	27
	13.07	Choice of Law and
    Jurisdiction	28
	13.08	No Jury Trial	28
	13.09	Notices	28
	13.10	Official Language	29
	13.11	Severability	29
	13.12	Amendment	29
	13.13	Entire Agreement	29
	 	 	 
	ANNEX
1            Development Plan	32
	ANNEX
2            LTS Equipment and Payment Schedule	33
	ANNEX
3            Confidentiality Agreement May 13, 2016 as amended	34
	ANNEX
4            Certificate of LTS Product Liability Insurance	35
	ANNEX
5            API Specifications	36




 




    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
3


     


    

 


PROCESS
DEVELOPMENT AGREEMENT


 


THIS
AGREEMENT, made and effective as of this 17thday of December, 2018 (“Effective Date”) by and between LTS LOHMANN Therapie-Systeme
AG, company organized and existing under the laws of Germany, having its executive offices and principal place of business at
Lohmannstraße 2, 56626 Andernach, Germany (hereinafter called “LTS”) and INTEC PHARMA Ltd., a corporation organized
and existing under the laws of the State of Israel, having its executive offices and principal place of business at 12 Hartom
Street, P.O. Box 45219, Jerusalem, Israel (hereinafter called “INTEC” and as further defined, below).


 


Individually
referred to as a “Party” and jointly referred to as the “Parties”.


 


WITNESSETH


 


WHEREAS
INTEC has developed or owns rights to a certain delivery technology called “Accordion Pill” which is based on patents
under an exclusive license to INTEC and additional proprietary intellectual property and confidential know-how of INTEC;


 


WHEREAS
LTS has expertise in the formulation and manufacturing process of transdermal therapeutic systems and oral thin films and the
commercial manufacture of such formulations which is based on patents and additional proprietary intellectual property and confidential
know-how of LTS;


 


WHEREAS,
LTS and INTEC entered into a Term Sheet dated March 11, 2018 regarding scaling up of the manufacturing process for the Product
using the Accordion Pill technology containing the ingredients Carbidopa/Levodopa (the “Term Sheet”);


 


WHEREAS,
INTEC intends to distribute the Product by itself or through its licensees, successors or assigns as hereinafter defined;


 


WHEREAS,
INTEC wishes LTS to perform the scale-up, process development and establishes the commercial manufacturing of the Product;


 


NOW
THEREFORE, in consideration of the premises and mutual covenants and conditions set forth herein, the Parties agree as follows:


 



    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
4


     


    

 


Article
I Definitions


 


General


 


When
used in this Agreement, each of the following terms shall have the meaning set forth in this Article I.


 


Wherever
used in this Agreement


 


		(a)	words
                                         of any gender include each other gender;



 


		(b)	words
                                         using the singular or plural number also include the plural or singular number, respectively;



 


		(c)	the
                                         terms “hereof”, “herein”, “hereunder”, “hereby”
                                         and derivative or similar words refer to this entire Agreement;



 


		(d)	the
                                         terms “Article” or “Section” refer to the specified Article or
                                         Section of this Agreement;



 


		(e)	The
                                         titles of the Articles and Sections of this Agreement are for general information and
                                         reference only, and this Agreement shall not be construed by reference to the titles.



 


		1.01	“ACCORDION
                                         PILL”



 


The
term “Accordion Pill” shall mean a gastro-retentive oral drug delivery dosage form, comprising a multi-layered drug
delivery system composed of a drug-containing polymeric matrix, the system is folded with multiple undulating pleats, and the
folded system is within a capsule.


 


		1.02	“ACCORDION
                                         PILL PRODUCTION LINE”



 


The
term “Accordion Pill Production Line” shall mean [***]


 


		1.03	“ACTIVE
                                         PHARMACEUTICAL INGREDIENT/ API”



 


“Active
Pharmaceutical Ingredient” or “API” shall mean Carbidopa and Levodopa with specifications as set forth Annex
5 (“API Specifications”).


 



    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
5


     


    

 


		1.04	“Affiliate”



 


“Affiliate”
shall mean any entity which controls, is controlled by, or is under common control with a Party. For purposes of this definition,
a Party shall be deemed to control another entity if it owns or controls, directly or indirectly, at least fifty percent (50%)
of the voting equity of such other entity (or other comparable ownership interest or voting power in an entity other than a corporation)
or if it has management control of the other entity.


 


		1.05	“Agreement”



 


“Agreement”
shall mean this Process Development Agreement and the annexes thereto.


 


		1.06	“BUSINESS
                                         DAY”



 


“Business
Day” shall mean any day (other than Saturdays, Sundays and Public Holidays) on which LTS is opened for business in Andernach,
Germany.


 


		1.07	“Clinical
                                         Samples”



 


“Clinical
Samples” shall mean samples and placebos of the Product supplied to INTEC for purposes of evaluation by INTEC in a clinical
study.


 


		1.08	“CMC
                                         Part”



 


“CMC
Part” shall mean the Chemistry, Manufacturing and Controls part of regulatory submissions for the product (drug master file
or equivalent in other territories).


 


		1.09	“Commercially
                                         Reasonable Efforts”



 


“Commercially
Reasonable Efforts” shall mean [***].


 




    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
6


     


    

 


		1.10	“COMPONENTS”



 


“Components”
shall mean, collectively, all raw materials, excipients and materials required to manufacture and package for performing the Development
Activities other than API.


 


		1.11	“Control”



 


“Control”
(including any variations such as “Controlled” and “Controlling”), in the context of intellectual property
or other rights, shall mean rights sufficient to enable a person to grant another person ownership, access, a license or sublicense
(as applicable) to such intellectual property or other rights, subject to any applicable terms and conditions, without


 


		(a)	requiring
                                         the consent of third party or



 


		(b)	violating
                                         the terms of an agreement with a third party.



 


		1.12	“Defective
                                         Product”



 


“Defective
Product” shall mean Product and/or Clinical Samples that do not comply with the Specifications or, in the case of Clinical
Samples, not manufactured according to cGMP.


 


		1.13	“Development
                                         Activities”



 


“Development
Activities” shall mean the activities as set forth in the Development Plan or additional activities that the Parties may
agree upon in connection with the development of the manufacturing process for the Product (including, but not limited to, qualification
and validation of the manufacturing process).


 


		1.14	“Development
                                         Plan”



 


“Development
Plan” shall mean the plan, which is attached hereto as Annex 1 setting forth the activities to be performed hereunder and
the prospective timelines for such activities starting with the execution of the Agreement.


 


		1.14	“INTEC”



 


“INTEC”
shall mean INTEC PHARMA, Ltd. and its Affiliates, successors and assigns.


 




    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
7


     


    

 


		1.15	“INTEC
TECHNOLOGY”



 


“Intec
Technology” shall mean the delivery technology called “Accordion Pill” which is based on patents under an exclusive
license to INTEC and additional proprietary Intellectual Property and confidential know-how of INTEC.


 


		1.16	“INTELLECTUAL
PROPERTY”



 


“Intellectual
Property” shall mean any and all rights in and/or to (a) patents; (b) inventions, discoveries, utility models and improvements
(whether or not capable of protection by patent or registration); (c) copyright and related rights; (d) design rights; (e) trademarks
and service marks; (f) business or trade names, domain names; (g) database rights; (h) confidential information, know-how, trade
secrets; and (i) other intellectual property rights; in each case whether registered or unregistered and including all applications
(or rights to apply) for, and renewals or extensions of, such rights and all similar or equivalent rights or forms of protection
which subsist or will subsist now or in the future in any part of the world.


 


		1.17	“LTS
TECHNOLOGY”



 


“LTS
Technology” shall mean LTS’ expertise in the formulation and manufacturing process of transdermal therapeutic systems
and oral thin films and the commercial manufacture of such formulations which is based on patents and additional proprietary Intellectual
Property and confidential know-how of LTS.


 


		1.18	“Manufacturing
Agreement”



 


“Manufacturing
Agreement” shall mean the manufacturing and supply agreement to be negotiated between the Parties for the manufacture and
supply of the Product as set forth in Article 2.02 of this Agreement.


 


		1.19	“Product”



 


The
term “Product” shall mean an Accordion Pill containing the API according to the Product properties set forth in the
Specifications.


 


		1.20	“Project”



 


“Project”
shall mean cooperation of the Parties under this Agreement with the objective to perform the Development Activities.


 



    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
8


     


    

 


		1.21	“Specifications”



 


“Specifications”
shall mean the written specifications to be developed by the Parties for the raw materials of Product and for the manufacturing
and quality control of the Product and/or Clinical Samples, including any and all additions and amendments to the same made in
writing by the Parties during the course of the Project.


 


Article
II Cooperation; Scope of Work


 


		2.01	The
                                         Parties shall duly and exclusively cooperate during the course of the Project.



 


		2.02	In
case that the respective first regulatory market authorisation grants the market authorisation for the Product, the Parties agree
that LTS shall exclusively manufacture the Product for INTEC and/or its licensees, successors or assigns for as long as the Parties’
relationship has not been terminated in accordance with the terms hereof or of the Manufacturing Agreement to be negotiated and
entered into by the Parties (subject to the execution of the Manufacturing Agreement, and the standard termination provisions
included therein) and INTEC and/or its licensees shall collaborate exclusively in the scaling-up of Product with LTS and LTS shall
supply all of INTEC’s and/or its licensees requirements of Product.



 


		2.03	LTS
shall be responsible for the Development Activities. INTEC shall be responsible
for all clinical trials and any other activities required for the registration and commercialization of the Product which are
not part of the Development Activities.



 


		2.04	All
Development Activities are subject to the Parties providing the necessary manufacturing equipment as set forth in Article III,
including but not limited to the Accordion Pill Production Line and LTS Equipment as set forth in Annex 2 attached hereto
which may be amicably amended by the Parties from time to time based on the Project progress.



 



    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
9


     


    

 


Article
III EQuipment


 


		3.01	The
Accordion Pill Production Line shall be owned by INTEC and placed in LTS’ facility during the entire term of the Agreement.
In addition, LTS shall not [***] which is considered as Confidential Information (as defined in the CDA set forth in Annex 3),
[***]. To the extent required, INTEC and LTS shall execute all necessary agreements and documents to in order to reflect INTEC’s
ownership rights hereunder.



 


		3.02	The
                                         Accordion Pill Production Line shall be operated and maintained by LTS as follows:



 


		(a)	INTEC
shall be responsible for and carry out the acceptance procedure with the supplier of the Accordion Pill Production Line upon the
completion of its installation at LTS’ facility with assistance, as required, and prior consultation with LTS personnel.
INTEC shall handle any warranty claims against the supplier of the Accordion Pill Production Line and shall be responsible for
providing a working Accordion Pill Production Line to use for the Development Activities.



 


		(b)	[***]
during the term of the Agreement and shall be responsible for the proper operation and maintenance of the Accordion Pill Production
Line in compliance with the manufacturer’s and INTEC’s specifications for the Accordion Pill Production Line.



 


		(c)	For
any maintenance and/or repair works - including, but not limited to, wear parts - on the Accordion Pill Production Line LTS believes
to be necessary LTS shall be required to execute such work on behalf of INTEC including, but not limited to, the mandating of
external service providers. Any costs incurred to such works shall be borne by LTS up to an [***]. Any additional costs for such
works carried out by LTS or any third party on behalf of INTEC [***] shall be borne by INTEC subject to INTEC’s prior approval
which shall not be unreasonably withheld.



 



    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
10


     


    

 


		(d)	LTS
shall be entitled to make minor adjustments on the Accordion Pill Production Line at its own discretion that lead to an enhancement
of performance and/or quality. LTS shall inform INTEC about any planned material improvement as soon as feasible and shall obtain
INTEC’s approval prior to implementation which shall not be unreasonable withheld.



 


		(e)	In
case of emergency or any accident LTS shall be entitled to initiate any necessary actions on behalf of INTEC.



 


		(f)	For
any of the activities LTS carries out on behalf of INTEC under this Section 3.02 LTS shall only be liable for any damages resulting
from such initiated actions, but LTS shall in no event be liable for any lost profits as set forth in Section 11.06.



 


		3.03	LTS
and INTEC shall make the actual investments into the necessary production equipment as set forth in Annex 2 (“LTS
Equipment”) which may be amicably amended by the Parties from time to time based on the Project progress as follows:



 


		(a)	INTEC
shall bear the total investment sum incurred by LTS for the LTS Equipment (“Intec Share”) that is necessary according
to the decision of the technical working group for and solely related to the Project.



 


		(b)	LTS
shall reimburse INTEC for the Intec Share by reducing the commercial Product price by [***] % [***] per unit until the total amount
of the Intec Share is reimbursed. In the event that INTEC provides notice to LTS that INTEC has decided not to continue with the
Project or with the commercialisation of the Product, LTS shall be entitled in its sole discretion to either (i) retain the LTS
Equipment or parts thereof by reimbursing to INTEC the actually incurred Intec Share for the LTS Equipment or parts thereof minus
LTS’ investment under the LTS Share above the first [***] of such investment, and in any event LTS may not take more than
€ 2 million (two million Euro) of deduction or (ii) transfer the LTS Equipment or parts thereof to INTEC at INTEC’s
costs by INTEC reimbursing to LTS LTS’ investment under the LTS Share above the first [***] of such investment, and in any
event in an amount not more than € 2 million (two million Euro) in total reimbursement by INTEC.



 



    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
11


     


    

 


		(c)	The
LTS Equipment shall be owned by LTS and LTS shall be responsible for the maintenance, repair and improvements of the LTS Equipment.



 


		(d)	In
addition, LTS shall upgrade the space dedicated to INTEC’s Product manufacturing and maintaining that and its Andernach
facility to GMP standard and to expand its facility in order to establish the production of the Product. Any necessary investments
related to such upgrade shall be borne by LTS up to an amount [***] and any investment amount exceeding [***] (“LTS Share”).
The amount of the actual gap in the LTS Share as set forth above, not to exceed € 1 million (one million Euro), shall be
borne by INTEC and such contribution to the investment shall be due upon the announcement of the results of the phase III clinical
study by INTEC or October 31, 2019 whatever occurs earlier. LTS shall be entitled to invoice the amount to INTEC with payment
due within 30 (thirty) days of receipt of LTS’ invoice.



 


		3.04	The
                                         LTS Equipment shall be purchased by LTS on behalf of INTEC on INTEC’s costs by
                                         LTS providing a purchase order to INTEC for INTEC’s approval which shall not be
                                         unreasonably withheld.



 


		3.05	LTS
                                         shall invoice the costs for such purchases of equipment to INTEC in the first week of
                                         each month according to the payment schedule set forth in Annex 2 which may be
                                         amicably amended by the Parties from time to time based on the Project progress and according
                                         to the payment terms set forth in Section 7.02.



 


		3.06	LTS
                                         shall solely use the LTS Equipment to manufacture the Product for INTEC hereunder until
                                         (a) the [***] of the launch date in the first country or (b) INTEC fails to place binding
                                         orders in the annual  amount of [***] units commencing on the [***] anniversary
                                         of the commercial launch date, whichever occurs earlier. Upon occurrence of Section 3.06
                                         (a) or (b) as set forth above LTS shall be entitled to use the LTS Equipment for any
                                         product other than Product, provided such use does not negatively impact INTEC’s
                                         production of Product. However, in case that Section 3.06 (b) occurs and the LTS Equipment
                                         has not been fully reimbursed by LTS according to Section 3.03 (b) the Parties shall
                                         discuss reasonable mechanism to allow INTEC to recoup the Intec Share.



 



    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
12


     


    

 


Article
IV Contribution of LTS


 


		4.01	LTS
                                         Contribution



 


LTS
shall use its Commercially Reasonable Efforts to perform the Development Activities. LTS shall document the Development Activities.
LTS shall purchase, qualify, test, inspect and approve all Components for the Development Activities at its costs.


 


		4.02	Changes
                                         to the Development Plan and additional LTS activities



 


Any
changes to the Development Plan, additional LTS activities or changes to such additional activities shall only become valid upon
the prior written agreement of the Parties.


 


		4.03	Estimated
                                         timelines and costs



 


LTS
shall use its Commercially Reasonable Efforts to perform the Development Activities within the timelines set forth in the Development
Plan. The assessment of employee-hours as set forth in the Development Plan is based on LTS’ best estimates and is
subject to variance. LTS shall advise INTEC monthly on each Development Activity as listed in the Development Plan,
the aggregate hours expended for the work performed in that month together with a forecast of hours to be expended in the following
month including a forecast for the completion of each remaining Development Activity.  In the event LTS determines
or forecasts that the employee-hours required to complete each  element of the Development Plan will
exceed the amount as set forth in the Development Plan by more than [***], LTS shall provide a basis for the variance and INTEC
shall have 10 (ten) Business days to challenge the variance costs. No response by INTEC to LTS’ provided variance shall
be deemed as acceptance by INTEC thereof. In the event the Parties do not resolve the variance with two (2) months after
LTS’ receipt of INTEC challenge, the Parties shall submit the variance to the Parties’ steering committee (to be established)
for resolution.   Employee-hours charged by LTS under this Agreement shall not include time expended by [***] of the
employees working on the Project. 


 


In case of agreement of additional activities by the Parties, the foregoing shall also
apply to these additional activities accordingly.


 



    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
13


     


    

 


		4.04	LTS’
                                         Support of Registration



 


LTS
shall provide to INTEC in a timely manner the information required for preparing the CMC Part of INTEC’s regulatory filings for
the Product in the USA and as contemplated in the Development Plan.


 


In
the event INTEC wishes additional support from LTS for the registration of the Product any such activities shall be subject to
the terms and conditions of this Agreement and a written agreement defining LTS’ compensation for such support.


 


Any
man-hours resulting from such additional support shall not be taken into consideration for determining (according to Section 4.03)
whether the employee-hours set forth in the Development Plan would be exceeded or not.


 




    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
14


     


    

 


		4.05	Audit
                                         at LTS



 


LTS
will permit an authorized representative of INTEC and/or its Affiliates upon written reasonable advance notice to conduct a quality
audit at LTS’ facility at reasonable times under such conditions as LTS may reasonably require in order to protect the confidentiality
of its own and its other customer’s proprietary and confidential information.


 


		4.06	QUALITY
                                         AGREEMENT



 


The
pharmaceutical aspects of the manufacturing of Clinical Samples and the division of responsibilities between the Parties in relation
to the manufacturing and release of the Clinical Samples, including but not limited to the obligations of each Party with respect
to the raw materials, shall be regulated in a separate quality agreement (“Quality Agreement”) between the Parties.


 


Article
V Contributions of INTEC


 


		5.01	API
                                         Supply



 


INTEC
shall deliver or have delivered to [***] such quantities of API at such times as LTS reasonably requests for the Development Activities
at no cost for LTS. All API supplied hereunder shall be utilized by LTS solely for conducting the Development Activities and any
unused quantities shall be either returned to INTEC or destroyed at INTEC’s cost and risk subject to INTEC’s sole
discretion.


 


		(a)	INTEC’s
Compliance with API Specifications



 


INTEC
represents and warrants that API delivered under this Agreement conforms to the API Specifications as set forth in Annex 5 and
that it has been manufactured according to cGMP and all other applicable statutes, laws and regulations and is suitable and ready
to be used for the Development Activities or the manufacture of Clinical Samples. Upon the successful transfer and validation
of the methods LTS shall [***] all such API supplies intended for GMP-use according to the API Specifications set forth in
Annex 5. In case that the API does not conform with the API Specifications INTEC shall promptly replace and deliver the necessary
quantities of API to LTS. LTS shall bear the liability for conducting such testing of the API solely in the event of LTS’
willful misconduct and/or gross negligence. LTS shall bear the costs of replacement of such wrongly tested API used for Development
Activities. In any case, LTS shall bear the expenses for investigating the root cause; all other liability shall be excluded.


 



    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
15


     


    

 


		(b)	Audit
                                         at Supplier of API



 


If
it is required by law, INTEC shall enable authorized representatives of LTS and/or its Affiliates upon written reasonable advance
notice to inspect at reasonable times the manufacturing process and storage of the API supplies, under such conditions as INTEC
or any supplier of the API may reasonably require in order to protect the confidentiality of its and its other customer’s proprietary
and confidential information.


 


		(c)	During
the course of the execution of this Agreement, INTEC and LTS shall cooperate on the execution of an analytical methods transfer
for those analytical methods required for the testing and release of incoming API so that LTS may assume responsibility for API
testing and release upon the implementation of the Manufacturing Agreement.



 


		5.02	DATA
                                         TRANSFER



 


INTEC
shall transfer to LTS all technical documents, data, know-how and other information necessary to scale-up and establish the manufacturing
process to qualify, test manufacture and supply the Product to INTEC (including the Product formulation, Specification, analytical
methods and manufacturing instructions) and make available to LTS INTEC’s qualified personnel for both on-site and off-site
support of the scale-up at LTS’ facility with respect to qualification and validation and Product manufacturing. All data
obtained by both parties during the development at LTS shall be shared with both parties according to the Development Plan.


 


		5.03	Evaluating
                                         Results



 


INTEC
shall duly evaluate the results in order to promote the Project.


 




    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
16


     


    

 


		5.04	Clinical
                                         Trials



 


INTEC
shall be responsible for planning and conducting all clinical trials of the Product. INTEC shall be the sole owner of all clinical
data and all results of the clinical trials. INTEC agrees to share the top line results with LTS of any relevant clinical trials
relating to the Product.


 


		5.05	Registration
                                         of Products



 


INTEC
shall (i) be responsible for preparing the applicable regulatory documents and filings for registration and approval of Product,
(ii) use only such documents created by LTS under the Development Activities approved for such filing purpose and (iii) inform
LTS of such filing and/or approvals in due time.


 


Article
VI  TECHNICAL WORKING GROUP


 


		6.01	Both
parties have established a joint technical working group with named representatives (project leaders) to discuss adjusting the
Development Activities and Development Plan, and determine and follow-up regulatory, analytical and process related needs (e.g.
for IND, NDA purposes). In case additional development activities not included in the Development Plan are requested, such activities
shall be agreed upon in writing by the joint technical working group regarding related costs and time-frame



 


Article
VII  Compensation


 


		7.01	INTEC
Funding of Development Activities



 


INTEC
shall compensate LTS for all employee-hours, actually incurred by LTS during its Development Activities spent in performing its
tasks according to the Development Plan. The total budget (which includes all materials and labour) is attached hereto together
with the Development Plan in Annex 1.


 




    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
17


     


    

 


		7.02	Payment
Terms



 


		(a)	INTEC
                                         shall compensate LTS for its Development Activities, which shall include services performed
                                         by third parties for any Development Activity, under the Development Plan which shall
                                         not exceed the total budget referred to in the Development Plan in Annex 1 and
                                         any additional services by LTS as mutually agreed upon at the following rate:



 


[***]


 


LTS
shall provide a monthly invoice setting forth the hours charged for LTS labor, materials and charges for third-party services
including VAT if applicable for each Development Activity identified in the Development Plan in Annex 1.


 


[***]


 


		(b)	LTS
                                         shall provide an invoice at the end of each month.



 


		(c)	LTS
                                         will verify and document the time devoted by LTS’ employees to the Project, and will
                                         submit an accounting monthly to INTEC. LTS will allocate employee-hours and production
                                         machine time consistently with its historical allocation practice and will provide INTEC
                                         with a sufficiently detailed explanation of such practice, upon request, so as to allow
                                         an independent certified public accountant or chartered accountant reasonably acceptable
                                         to INTEC to audit same.



 




    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
18


     


    

 


		7.03	Payment
                                         terms



 


		(a)	Maturity



 


INTEC
shall pay LTS the compensation provided for in Section 0 within [***] days upon receipt of the invoice from LTS. Payments shall
be made in euro (€).


 


		(b)	Overdue
                                         payments



 


Overdue
payments shall accrue interest at the rate of [***] on the first Business Day that any payments becomes overdue, until made.


 


		(c)	No
                                         Setoff



 


INTEC
shall not be entitled to exercise any right of setoff, net-out or deduction, take any credit, or assert any other defense arising
out of any transaction unless and until INTEC has obtained a final and non-appealable judgment against LTS in the amount asserted
by INTEC.


 


		7.04	Expenses



 


Each
Party shall bear all of the expenses of its own participation or related to its contribution or the performance of its obligations
under this Agreement unless provided for in this Agreement. In the event of unforeseen or extraordinary expenses LTS shall be
entitled to request an equitable allocation.


 


Article
VIII Confidentiality


 


		8.01	The
confidentiality agreement concluded between the Parties effective from May 13, 2016 (the “CDA”, attached hereto as
Annex 3), shall govern the exchange of information pursuant hereto, it being clarified that INTEC’s Technology shall
be deemed INTEC’s Confidential Information thereunder. The term of the confidentiality agreement is hereby amended such
that it will continue throughout the term of this Agreement and the Parties’ obligations thereunder shall survive the termination
hereof until 31 December 2029, provided however that expiration of such contractual restriction shall not derogate from INTEC’s
rights under its Patents and shall not in any manner be interpreted as a grant of right or license to Manufacture other Accordion
Pills than Product. The terms of this Agreement shall be treated as Confidential Information as defined under the confidentiality
agreement.



 



    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
19


     


    

 


ARTICLE
IX INTELLECTUAL PROPERTY


 


		9.01	INTEC
                                         shall own all Intellectual Property generated during such Project which directly relates
                                         to the Intec Technology and/or medical use/s thereof, including INTEC’s Intellectual
                                         Property covering the manufacturing process of the Accordion Pill, and any improvements
                                         thereto.



 


		9.02	LTS
                                         shall own all Intellectual Property directly related to the LTS Technology.



 


		9.03	(i)
                                         Any Intellectual Property generated during such Project which directly relates to the
                                         preparation of thin films which are introduced into (i.e. manufacturing process taking
                                         place outside of) the Accordion Pill Production Line, or any similar machine being used
                                         in the Project, and (ii) any other results and Intellectual Property generated during
                                         such Project which are not included in 9.01 or 9.02 and relate to the manufacturing processes,
                                         including web converting methods, which are of general applicability and may be used
                                         to produce products other than the Accordion Pill, shall be jointly owned by both Parties.
                                         Each Party can use this joint Intellectual Property on a royalty free basis and without
                                         the need for the other Party’s prior consent (the “License”).



 


		9.04	In
                                         case of LTS, such joint Intellectual Property may be used by LTS outside of this collaboration
                                         for any products except for Product or other Accordion Pills as long as the Parties exclusively
                                         cooperate with regard to the manufacturing of the Product or while LTS remains subject
                                         to the restrictions set forth in Section 10.1 hereunder.



 


		9.05	For
                                         avoidance of doubt, such License does not grant the right to use either Party’s
                                         solely owned Intellectual Property and confidential know-how, including the Intellectual
                                         Property set forth in Sections 9.01 and 9.02 for any other projects with third parties.



 



    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
20


     


    

 


Article
X Future Rights


 


		10.01	LTS
                                         shall not have the right to manufacture the Product or any of its components (including,
                                         for clarity, any other Accordion Pill) to any third party without the prior written consent
                                         from INTEC until the later of: (i) [***] or (ii) for as long as [***] continues, provided
                                         however that expiration of such contractual restriction shall not derogate from INTEC’s
                                         rights under its Intellectual Property and shall not in any manner be interpreted as
                                         a grant of right or license to manufacture Products or Accordion Pills.



 


Article
XI Liability and Indemnification


 


		11.01	Supply
                                         of Samples



 


All
deliveries of samples and Clinical Samples of Product shall be made [***].


 


		11.02	Replacement



 


LTS
will replace Defective Product at [***]. Such replacement shall be subject to INTEC (i) providing sufficient evidence of appropriate
and correct storage at all times after Product has been delivered by LTS (ii) providing notice specifying the nature of the defect
and the Product lot number of claimed Defective Product in the time period set forth hereunder but not later than [***] after
shipment. Should INTEC reject any Defective Product, INTEC shall deliver to LTS written notice of rejection within [***] after
receipt by INTEC of the applicable shipment or, in case of hidden defects within [***] after INTEC has taken notice of the defect.
LTS shall have the right to examine any claimed Defective Product before any such claim is honoured.


 




    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
21


     


    

 


		11.03	Product
                                         Liability



 


		11.03.1	In
addition, LTS shall hold INTEC harmless [***] from any claim, cost, expense and damage arising out of the use of Defective Product
(“Claims”) supplied by LTS to INTEC for clinical trials to the extent that:



 


		(i)	INTEC
(and/or its designated clinical research organization) acts in accordance with applicable laws and standards, such as GCP and
the Helsinki Declaration;



 


		(ii)	the
aforementioned claim, expense, damage or injury is not caused by the API supplied by INTEC to LTS for the manufacture of Product
and/or Clinical Samples according to Section 5.01.



 


A
certificate of LTS’ current product liability insurance is attached hereto as Annex 4. LTS shall employ its Commercially
Reasonable Efforts to maintain an insurance coverage similar to the coverage set forth in Annex 4.


 


		11.03.2	INTEC
shall bear all of the risk, cost and expenses related to the use of Product (incl. Clinical Samples) and shall be fully liable
and shall indemnify and hold harmless LTS from any damage, claims, costs and expenses (including reasonable attorney’s fees)
arising out of claims resulting from damage or injury to itself and its employees and any third party, for which LTS is not liable
according to this Section 0.



 


		11.03.3	The
restrictions on LTS’ liability shall not apply in the event of LTS’ willful misconduct.



 


		11.04	Volunteer
                                         Insurance



 


INTEC
shall maintain adequate clinical trial insurance coverage of at least an amount as required by applicable laws and as reasonable
and customary in the pharmaceutical industry considering the nature and extent of the clinical trials in question for any clinical
trial conducted by INTEC with the Product.


 



    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
22


     


    

 


		11.05	Acknowledgement



 


INTEC
acknowledges that the development of the manufacturing process by LTS is dependent on the quality of INTEC’s design of Product.


 


		11.06	No
                                         Indirect, Punitive or Exemplary Damages



 


Neither
Party shall be liable for indirect, special or consequential damages, lost profits and/or punitive damages, provided however,
that this shall not limit the indemnification obligations for third party claims as set forth in Article XI. This exclusion of
liability does not apply if such agreement would be invalidated by stringent law as it may be the case of intentional misconduct
or willful default.


 


		11.07	No
                                         warranty



 


Each
of the Parties acknowledges that the work to be performed hereunder is developmental and that nothing in this Agreement may or
shall be construed as a guarantee, representation or warranty, express or implied that the DEVELOPMENT ACTIVITIES will be successfully
PERFORMED,ACHIEVED within a certain period of time, fit for a particular use, ARE feasible of being manufactured, free from any
third party’s intellectual property rights, protected by patents of the Parties or marketable, nor that Inventions are patentable.


 


Article
XII Term and Termination


 


		12.01	Term



 


This
Agreement shall remain in effect until terminated in accordance with this Article XII or upon termination of the Manufacturing
Agreement.


 


		12.02	Either
Party hereto shall have the right in its discretion to terminate this Agreement at once by written notice to the other Party in
the event that the other Party by voluntary or involuntary action goes into liquidation or receivership; or dissolves or files
a petition for bankruptcy or reorganization or for suspension of payments or is adjudicated a bankrupt, becomes insolvent or assigns
or makes any composition of its assets for the benefit of creditors; or



 



    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
23


     


    

 


		12.03	If
                                         either Party shall be in default of any of its material obligations under this Agreement,
                                         the non-defaulting Party shall give the defaulting Party written notice of such default,
                                         upon which the defaulting Party shall have ninety (90) days to cure such default and/or
                                         establish that no default has occurred and/or in the event such default is incapable
                                         of cure by employing Commercially Reasonable Efforts within such ninety (90) days period
                                         to commence appropriate action to cure such default by employing Commercially Reasonable
                                         Efforts. In the event that a default remains uncured and/or the defaulting Party has
                                         not established that a default has not occurred and/or in case the default was incapable
                                         of cure within such ninety (90) days by using Commercially Reasonable Efforts the defaulting
                                         Party did not commence appropriate action to cure such default by employing Commercially
                                         Reasonable Efforts after ninety (90) days have elapsed, the non-defaulting Party may
                                         declare this Agreement terminated by written notice to the defaulting Party.



 


		12.04	INTEC
                                         shall have the right to terminate this Agreement by three (3) months written notice in
                                         case of a change of control of LTS subject to the following provisions:



 


		(i)	INTEC
                                         shall without undue delay and in no event later than twenty (20) Business Days after
                                         having been informed by LTS of an existing or upcoming event of change of control with
                                         respect to LTS notify LTS of its intention to terminate the Agreement.



 


		(aa)	If
prior to or during a period of twenty (20) Business Days following receipt by LTS of INTEC’s notification pursuant to sub
clause (i) or any other term agreed by the Parties in writing (“Grace Period”), LTS delivers to INTEC a written undertaking
of the new shareholder stating that even after the change of control LTS commits itself to fulfill its obligations under the Agreement
then INTEC shall not exercise the termination right under this Section 12.05.



 


		(bb)	If
the event that LTS does not deliver to INTEC the shareholder undertaking within the Grace Period then INTEC shall be free to exercise
the termination right under this Section 12.05. The termination right must be exercised within twenty (20) Business Days after
the lapse of the Grace Period.



 





		(ii)	Unless
otherwise agreed between the Parties in writing, any failure by INTEC to comply with any notification requirement within the notice
period set forth in this Section 12.05 shall operate as a waiver by INTEC of its termination right hereunder.


 



    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
24


     


    

 


		12.05	INTEC
shall have the right to terminate this Agreement or to revoke INTEC’s obligation to engage LTS on an exclusive basis, by
[***] written notice in case INTEC consummates a change of control or if INTEC sells or licenses the Product to a third party
in the framework of a Commercial License (as defined below) and such third party (licensee or acquirer) decides to not have the
Product manufactured by LTS (or not to have it manufactured exclusively by LTS), provided that the effective date of termination
or the end of exclusive basis in such event may not be prior to [***] from the Product’s commercial launch.



 


“Commercial
License” means a license permitting licensee to market and sell the Product in consideration for defined license fees and
compensation (i.e. excluding licenses granted in connection with feasibility, evaluation, collaboration, contracting or similar
agreements). For clarity, if the relevant agreement between the parties includes a preliminary option, e.g. feasibility or similar
phase, the Commercial License will be deemed executed for the purpose hereof only upon the entering into effect of the Commercial
License within such agreement, i.e. the permission to market and sell as defined above. INTEC shall notify LTS in writing within
twenty (20) Business days about the execution of or the entering into effect of the change of control or the Commercial License
whatever the case may be.


 


The
termination right (as opposed to the right to revoke the exclusivity) must be exercised within six (6) months following the consummation
of a charge of control or the execution of or the entering into effect of the Commercial License (whatever the case may be).


 



    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
25


     


    

 


		12.06	Surviving
                                         Rights



 


Neither
cancellation nor termination of this Agreement nor the execution of a Manufacturing Agreement shall relieve the Parties of their
obligations as to Confidentiality (Article VIII), Intellectual Property (Art. IX) and Liability and Indemnification (Art. XI).


 


Article
XIII Miscellaneous Provisions


 


		13.01	No
                                         Waiver



 


No
failure or delay by either Party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall
any single or partial exercise thereof preclude any other or further exercise or any other right, power or privilege.


 


		13.02	ASSIGNMENT



 


This
Agreement shall not be assignable by either Party hereto, in whole or in part, in fact or by operation of law, without the prior
written consent of the other Party, provided that each Party may assign its rights to an acquirer acquiring all or substantially
all of its assets or all of the Product assets, provided that such acquirer shall agree in writing to be bound to the other Party
by all of the terms of this Agreement.


 


		13.03	Involvement
                                         of Third Parties by LTS



 


		13.03.1	LTS
may have certain of its tasks or duties performed by one of its Affiliates, or, after written authorization of INTEC by a third
party under obligation of confidentiality, if same is necessary for the timely performance of the Development Activities, however,
LTS shall remain solely responsible for the performance of the Development Activities in accordance with the terms hereof. LTS
warrants that any tasks performed by an Affiliate shall fully comply with any applicable regulation relating to the manufacture
of the Product and that such performance by the Affiliate shall in no way delay or interfere with any applicable regulatory filing
or approval required for the Product unless otherwise agreed upon between the Parties. If LTS chooses to have certain of its tasks
or duties performed by one of its Affiliates or a third party according to the foregoing or if the Parties determine that the
Product shall be manufactured in the facilities of LTS’ Affiliates, then all licenses and rights in favor of LTS hereunder
shall be deemed to be granted to such LTS’ Affiliate or such third party for the period during which it is performing LTS’
tasks or duties or is manufacturing the Product.



 





		13.03.2	With
the written authorization of INTEC, which shall not be unreasonable withheld, LTS may assign all of its rights, obligations and
interests to a third party under obligations of confidentiality.


 



    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
26


     


    

 


		13.04	Involvement
                                         of Third Parties by INTEC



 


INTEC
may have certain of its tasks or duties performed by a third party


 


		(a)	upon
                                         prior written authorization of LTS which shall not be unreasonably withheld, and



 


		(b)	under
                                         an obligation of confidentiality no less stringent than provided for in this Agreement
                                         or in case such third party carries out its services on LTS’ premises under the
                                         obligation to execute a confidentiality agreement directly with LTS.



 


		13.05	No
                                         Agency



 


Nothing
in this Agreement shall be construed as an authorization for a Party to act as an agent for another.


 


		13.06	Force
                                         Majeure



 


Neither
Party shall be held responsible or shall be considered in default or liable to the other Party for, nor shall this Agreement be
terminated as a result of any delay or failure to perform any of its obligations hereunder, if such delay or failure results from
circumstances beyond the control of such Party, including requisition by any authority, the effect of any statute, ordinance or
governmental order or regulation, war, rebellion, terrorist action, insurrection, civil commotion, riot, strike, lockout, labor
disturbance, epidemic, disease, act of God, civil commotion, explosion, fire, earthquake, storm, accident, failure of public utilities,
common carriers or suppliers or the like, or any other circumstances, whether or not similar to the above causes and whether or
not foreseeable. The Parties shall use Commercially Reasonable Efforts to remove any such cause and shall resume performance under
this Agreement as soon as feasible whenever such cause is removed; provided, however, that the foregoing shall not be construed
to require either Party to settle any dispute with any third party, to commence, continue or settle any litigation, or to incur
any unusual or extraordinary expense.


 



    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
27


     


    

 


		13.07	Choice
                                         of Law and Jurisdiction



 


This
Agreement shall be exclusively governed by the laws of Switzerland. The Parties shall make all reasonable efforts to amicably
resolve any disputes which may arise out of or relating to the application of this Agreement. In the event that the Parties fail
to so resolve any dispute, then the dispute shall be finally settled by binding arbitration before a panel of three arbitrators
und the rules of Conciliation and Arbitration of the International Chamber of Commerce (ICC). Any arbitration pursuant to this
Agreement shall be conducted in the English language and shall be held Zurich, Switzerland. The decisions of the arbitrators shall
be rendered to the Parties in writing, and shall be final and binding. The costs and expenses of the arbitrators shall be borne
equally by the parties, but each Party shall bear its own expenses incurred in the proceedings. The arbitrators shall have no
authority to award punitive damages.


 


		13.08	No
                                         Jury Trial



 


THE
UNDERSIGNED PARTIES ACKNOWLEDGE THAT THE RIGHT TO TRIAL BY JURY IS A CONSTITUTIONAL ONE, BUT THAT IT MAY BE WAIVED AND AFTER CONSULTING
WITH COUNSEL, EITHER PARTY MAY KNOWINGLY AND VOLUNTARILY WAIVE ANY RIGHT TO TRIAL BY JURY IN THE EVENT OF LITIGATION REGARDING
THE PERFORMANCE OR ENFORCEMENT OF, OR IN ANY WAY RELATED TO, THIS AGREEMENT AND ANY AGREEMENT CONNECTED THERETO.


 


		13.09	Notices



 


Any
notice required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been sufficiently
given for all purposes if mailed by first class certified or registered mail, or commercial delivery service, postage prepaid.
Unless otherwise specified in writing, the mailing addresses of the Parties shall be as described above.


 



    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
28


     


    

 


		13.10	Official
                                         Language



 


English
shall be the language employed in all amendments to this Agreement, further agreements relating to the subject matter and all
correspondence and other communication and documentation by the technical working group.


 


		13.11	Severability



 


The
provisions of this Agreement shall be deemed severable. Therefore, if any part of this Agreement is rendered void, invalid or
unenforceable, such rendering shall not affect the validity or enforceability of the remainder of this Agreement and shall be
replaced by provisions that are economically similar; provided that if the part or parts which are void, invalid or unenforceable
as aforesaid shall substantially impair the value of the whole Agreement to either Party, that Party may cancel and terminate
this Agreement by giving written notice to the other Party.


 


		13.12	Amendment



 


This
Agreement may not be amended, supplemented or otherwise modified except by an instrument in writing signed by both Parties.


 


		13.13	Entire
                                         Agreement



 


This
Agreement, including the Appendices attached hereto, constitutes and contains the complete, final and exclusive undertaking and
agreement of LTS and INTEC hereto, and cancels and supersedes any and all prior negotiations, correspondence, understandings and
agreements whether oral or written, between the Parties regarding the subject matter hereof.


 



    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
29


     


    

 


IN
WITNESS WHEREOF, the Parties hereto have executed this Agreement.


 


	LTS
    LOHMANN Therapie-Systeme AG	 	INTEC
    PHARMA Ltd.
	 	 	 
	/s/
Klaudia Haczkiewicz                 /s/ Tim Ohnemueller	 	/s/
Walt A. Linscott
	(Signature)	 	(Signature)
	 	 	 
	Head
of Business Development      General Counsel	 	Walt A. Linscott, Chief Business Officer 
	(Name,
    Title)	 	(Name,
    Title)
	 	 	 
	Andernach,
December 21, 2018	 	Jerusalem,
December 21, 2019
	(Place,
    Date)	 	(Place,
    Date)


 




    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
30


     


    

 


List
of Annexes


 


		ANNEX
                          1	Development
Plan



 


		ANNEX
                          2	LTS
Equipment and Payment Schedule



 


		ANNEX
                          3	Confidentiality
Agreement May 13, 2016 as amended



 


		ANNEX
                          4	Certificate
of LTS Product Liability Insurance



 


		ANNEX
                          5	API
Specifications



 




    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
31


     


    

 


Annex
1


 


[***]


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 




    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
32


     


    

 


Annex
2


 


[***]


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 




    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
33


     


    

 


Annex
3


 


[***]


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 




    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
34


     


    

 


Annex
4


 


[***]


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 




    
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
 
35


     


    

 


Annex
5


 


[***]


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.


 


36